EPIX Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics through the use of its proprietary silico drug discovery technology to treat diseases of the central nervous system and lung conditions. Its therapeutic product candidates in development PRX-08066, a small-molecule inhibitor that completed Phase II clinical trials for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with chronic obstructive pulmonary disease; and PRX-07034, which completed Phase I studies for the treatment of cognitive impairment associated with schizophrenia. The company also offers Vasovist, an injectable intravascular contrast agent to provide enhanced imaging of the vascular system using magnetic resonance angiography. It has collaborations with SmithKline Beecham Corporation, Amgen Inc., and Cystic Fibrosis Foundation Therapeutics, Incorporated. The company was formerly known as EPIX Medical, Inc. and changed its name to EPIX Pharmaceuticals, Inc. in 2004. EPIX Pharmaceuticals, Inc. was founded in 1988 and is based in Lexington, Massachusetts. As of July 20, 2009, EPIX Pharmaceuticals, Inc. is in liquidation.

Nihon Medi-Physics Co., Ltd. is a Japanese joint venture company located in Koto-ku focused on pharmaceutical preparations. The firm was founded in 1973. Nobuhiko Tamura is the current CEO of the company.\nThe company says this about itself: Nihon Medi-Physics is engaging in ensuring stable supply and research and development of the products as a leading manufacturer of radiopharmaceuticals in Japan. Based on the technological proficiency and trust built over the years, the company is also working on research and development of \"Theranostics (a combination of therapy and diagnosis),\" which is a novel medical technology to provide optimal medical service to each patient, as well as on the dissemination of nuclear medicine in Asian countries by licensing its products. The company will continue contributing to society by creating values as a life science company.

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche. Genentech was founded in 1976 by [Robert Swanson](https://www.crunchbase.com/person/robert-a-swanson) and [Herbert Boyer](https://www.crunchbase.com/person/herbert-w-boyer). It is headquartered in South San Francisco, C.A.

Izun Pharmaceuticals is a biopharmaceutical company with a product portfolio of powerful non-steroidal topical oral anti-inflammatory therapies with superior efficacy and safety to current periodontal treatments.

Since 1955, WAKUNAGA’s mission statement is “they serve the public’s health from the entrepreneur spirit and contribute to the society through the development of outstanding products by using the unique technology” . WAKUNAGA has been moving forward in developing reliable healthcare products to maintain your health.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

The American Red Cross (ARC), also known as the American National Red Cross, is a humanitarian organization that provides emergency assistance, disaster relief, and education inside the United States. It is the designated U.S. affiliate of the International Federation of Red Cross and Red Crescent Societies. It is the largest single supplier of blood and blood products in the United States, collecting and processing approximately 40 percent of the blood supply and distributing it to about 2,600 hospitals and transfusion centers nationwide. The organization researches and tests to protect the safety of the blood supply. It was among the first to develop and implement testing for many infectious diseases including, HIV, hepatitis B and C viruses, West Nile virus, and Chagas disease. The ARC operates the nationwide hemovigilance program to examine donor and patient adverse reactions. Data from the program is used to enhance blood product quality and safety The ARC serves on key committees of AABB and other blood-related organizations, and works closely with the U.S. Food and Drug Administration (FDA). The American Red Cross was established in 1881 and is headquartered in Washington, District of Columbia with 39 immunohematology reference laboratories nationwide.

Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006 it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011. Schering was listed on the Frankfurt Stock Exchange and had 26,000 employees as of 2004.

Nipro Corp. engages in the manufacture and sale of medical equipment, pharmaceutical products, and glass products. Its operations are carried out through the following segments: Medical related, Pharmaceutical related, Pharma Packaging, and Others. The Medical related segment provides injection and infusion-related products, artificial organ-related products, functional products, and dialysis and diabetes-related products. The Pharmaceutical related segment involves the manufacture and sale of injections, oral agents, and pharmaceutical kit products. The Pharma Packaging segment provides glass products for bottle tubes, ampoules, thermos-use, and lighting. The Others segment includes real estate leasing. The company was founded on July 8, 1954 and is headquartered in Osaka, Japan.

Aplagon Oy provides pharmaceutical discovery and development services. It develops locally acting antithrombotic products (APACs). The company was founded by Riitta Lassila and Yrjo Sakari Lassila in 2009 and is headquartered in Helsinki, Finland.

Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA.

Sanhome was one of the first group of companies which have been awarded GMP certificate in China. The company has been certificated as ‘state high-tech innovation enterprise’ by China Ministry of Science & Technology in 2003, has been ranked in top 100 pharmaceutical enterprises in China since 2009, and has been awarded ‘Top 100 pharmaceutical enterprises’ and ‘Top 50 pharmaceutical enterprises in growth’ by All-China Federation of Industry & Commerce in 2015.

Changzhou Runnuo Biotechnology Co., Ltd., established on 2014-08-14, Business scope includes biological,Pharmaceutical technology development,Technical Services,technology transfer,technical consulting.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Manufactures pharmaceuticals and diagnostic substances

Board of Trustees of Michigan State University, part of Michigan State University, is an American company that trusts Except Educational Religious.

Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany.

Peptron is a biotech company developing a wide range of peptide and small molecule based drugs to treat chronic and life-threatening disorders. Its initial focus is to provide long-term cure for neurodegenerative, cancer and endocrine related diseases. Peptron integrates the extensive experience of peptide research, drug development and expertise in drug delivery technologies for more than 15 years combined with a patients-focused approach driven by excellence.